ERBB2 and neoplasm: The DESTINY-PanTumor01 trial included patients based on NGS- or PCR-detected presence of prespecified activating HER2 mutations (and excluded any tumor expressing HER2 at the 3+ level by IHC) and showed an ORR of 29.4% across tumor types (Li et al., 2024).